Cancer immunotherapies can be further divided into several sub-categories such as oncolytic viral therapies like reovirus and adenovirus, cancer vaccines that utilize tumor-specific antigens to initiate an immune response, cytokine therapies like IL-2 and IFN-α that were initially used against melanoma, immune checkpoint inhibitors used to stimulate anti-tumor immune responses by disrupting inhibitory signals, and adoptive cell therapies (ACTs) which use ex vivo expanded and engineered immune cells [2,3,4,5,6,7]. This evidence concerns the gene IL2 and neoplasm.